Medicines authorised with a summary of the risk management plan (sRMP)

In connection with the approval of a risk management plan for a medicinal product for human use, a summary of the risk management plan for the medicinal product is prepared and made publicly available in accordance with the pharmacovigilance legislation which came into force in July 2012.

The summary is prepared by the marketing authorisation holder and approved by the Danish Medicines Agency. On the EMA's website, you can find the summaries of risk management plans for medicinal products with an authorisation granted under the Centralised Procedure.

You can find the summaries of risk management plans by searching for the product name or the active substance.

You can also find a summary of risk management plan by clicking the first letter of the relevant product name below.

Since medicinal products sometimes change names there can be divergent names in the summary of the risk management plan and on this website.

The name on the website will always be the most recently approved name for the product.

The name in the summary of the risk management plan can be a previously approved name of the product or the name(s) of the active substance(s).

Product Name Pharmaceutical Form Strength Active Substance Approval Date
Zafrilla tabletter; 2 mg DIENOGEST 13/12/2018
Zanosar pulver til koncentrat til infusionsvæske, opløsning; 1 g Streptozocin 28/02/2018
Zarator filmovertrukne tabletter; 10 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zarator tyggetabletter; 10 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zarator filmovertrukne tabletter; 20 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zarator tyggetabletter; 20 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zarator filmovertrukne tabletter; 40 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zarator tyggetabletter; 40 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zarator tyggetabletter; 5 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zarator filmovertrukne tabletter; 80 mg ATORVASTATINCALCIUM (trihydrat) 18/04/2018
Zavedos injektionsvæske, opløsning; 1 mg/ml IDARUBICINHYDROCHLORID 03/07/2017
Zavedos pulver til injektionsvæske, opløsning; 10 mg IDARUBICINHYDROCHLORID 22/04/2016
Zavedos pulver til injektionsvæske, opløsning; 5 mg IDARUBICINHYDROCHLORID 22/04/2016

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


...